Evidence map›Paper›PMID 33333996›Full record

ReviewInternational journal of molecular sciences2020

Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?

Stanislav R Kurpe, Sergei Yu Grishin, Alexey K Surin, Alexander V Panfilov, Mikhail V Slizen, Saikat D Chowdhury, Oxana V Galzitskaya

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Creation of New Antimicrobial Peptides.International journal of molecular sciences · 2023
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Peptide from NSP7 is able to form amyloid-like fibrils: Artifact or challenge to drug design?Biochimica et biophysica acta. Proteins and proteomics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Stanislav R KurpeInstitute of Protein Research, Russian Academy of Sciences, 142290 Pushchino, Russia.
Sergei Yu GrishinInstitute of Protein Research, Russian Academy of Sciences, 142290 Pushchino, Russia.ORCID 0000-0001-7373-9808
Alexey K SurinInstitute of Protein Research, Russian Academy of Sciences, 142290 Pushchino, Russia.
Alexander V PanfilovInstitute of Protein Research, Russian Academy of Sciences, 142290 Pushchino, Russia.
Mikhail V SlizenInstitute of Protein Research, Russian Academy of Sciences, 142290 Pushchino, Russia.
Saikat D ChowdhuryDepartment of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur 741246, West Bengal, India.ORCID 0000-0001-8479-3084
Oxana V GalzitskayaInstitute of Protein Research, Russian Academy of Sciences, 142290 Pushchino, Russia.ORCID 0000-0002-3962-1520
Institute of Protein Research · RUIndian Institute of Science Education and Research Kolkata · INInstitute of Bioorganic Chemistry · RUInstitute of Theoretical and Experimental Biophysics · RU

Funding

Russian Science Foundation 18-14-00321
6 · The paper itself

Abstract

At present, much attention is paid to the use of antimicrobial peptides (AMPs) of natural and artificial origin to combat pathogens. AMPs have several points that determine their biological activity. We analyzed the structural properties of AMPs, as well as described their mechanism of action and impact on pathogenic bacteria and viruses. Recently published data on the development of new AMP drugs based on a combination of molecular design and genetic engineering approaches are presented. In this article, we have focused on information on the amyloidogenic properties of AMP. This review examines AMP development strategies from the perspective of the current high prevalence of antibiotic-resistant bacteria, and the potential prospects and challenges of using AMPs against infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Indexed as

COVID-19 Drug TreatmentAmyloidogenic ProteinsAnimalsCoronavirus InfectionsCOVID-19HumansPore Forming Cytotoxic ProteinsProteomeSARS-CoV-2Amyloidogenic ProteinsPore Forming Cytotoxic ProteinsProteomeamyloidogenic regionsantibacterial peptidescoronavirus disease 2019 (COVID-19)mass spectrometryproteomesevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)toxicity

Identifiers

PMID33333996
PMCPMC7765370
OpenAlexW3112680793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.